Trial Profile
A Randomized, Double-blind, Multiple-dose, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ACZ885 in Patients With Newly Diagnosed Type-1 Diabetes Mellitus (T1DM).
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Novartis
- 31 Mar 2011 United Kingdom Clinical Research Network record identified and integrated.
- 22 Mar 2011 New trial record